Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI1 | Q9ULC6 | 5/20 | 0.43 |
| ▸ | PADI4 | Q9UM07 | 5/20 | 0.43 |
| ▸ | PADI2 | Q9Y2J8 | 4/20 | 0.43 |
| ▸ | PDE4A | P27815 | 3/20 | 0.43 |
| ▸ | PADI3 | Q9ULW8 | 3/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.39 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2876318 | 0.86 | NPY4R (0.45) | C3AR1 | |
| SCHEMBL5673367 | 0.86 | KISS1R (0.46) | — | |
| SCHEMBL188589 | 0.84 | C3AR1 (0.52) | PADI1PADI4PADI2PDE4APADI3 | |
| SCHEMBL7925397 | 0.84 | C3AR1 (0.52) | PADI1PADI4PADI2PDE4APADI3 | |
| SCHEMBL188590 | 0.84 | C3AR1 (0.52) | PADI1PADI4PADI2PDE4APADI3 | |
| SCHEMBL10654174 | 0.82 | PADI1 (0.46) | PADI1PADI4PADI2PDE4APADI3 | |
| SCHEMBL11328555 | 0.82 | PADI1 (0.42) | PADI1PADI4PADI2PDE4APADI3 | |
| SCHEMBL5943119 | 0.82 | PADI1 (0.42) | PADI1PADI4PADI2PDE4APADI3 | |
| SCHEMBL9662910 | 0.82 | PADI1 (0.42) | PADI1PADI4PADI2PDE4APADI3 | |
| SCHEMBL7445644 | 0.82 | NPY4R (0.35) | C3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710033-A1 | NUCLEAR-TARGETED DNA REPAIR ENZYMES AND METHODS OF USE | Oregon Health & Science University (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200283745-A1 | NUCLEAR-TARGETED DNA REPAIR ENZYMES AND METHODS OF USE | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2020-09-10 | — | — | US | disclosed |
| EP-2205623-B1 | PROTECTIVE SKIN CARE TETRAPEPTIDES | HELIX BIOMEDIX INC (US) | 2016-03-16 | — | — | EP | disclosed |
| EP-2512498-B1 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | HELIX BIOMEDIX INC (US) | 2015-09-16 | — | — | EP | disclosed |
| US-8597902-B2 | Peptide protection against ultraviolet light toxicity | HELIX BIOMEDIX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| EP-2512498-A2 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | Helix Biomedix Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120225023-A1 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | HELIX BIOMEDIX, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2011063090-A2 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | HELIX BIOMEDIX INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| EP-2205623-A1 | PROTECTIVE SKIN CARE TETRAPEPTIDES | Helix Biomedix Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090142280-A1 | Protective skin care peptides | HELIX BIOMEDIX INC. | 2009-06-04 | — | — | US | disclosed |
| WO-2009058244-A1 | PROTECTIVE SKIN CARE TETRAPEPTIDES | HELIX BIOMEDIX INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20070189982-A1 | Diagnostics and treatments of Periodontal disease | THE UNIVERSITY OF MELBOURNE (AU) | 2007-08-16 | — | — | US | disclosed |
| EP-0858504-A4 | DIAGNOSTICS AND TREATMENTS OF PERIODONTAL DISEASE | UNIV MELBOURNE (AU) | 2002-12-04 | — | — | EP | disclosed |
| EP-0858504-A1 | DIAGNOSTICS AND TREATMENTS OF PERIODONTAL DISEASE | THE UNIVERSITY OF MELBOURNE (AU) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997016542-A1 | DIAGNOSTICS AND TREATMENTS OF PERIODONTAL DISEASE | THE UNIVERSITY OF MELBOURNE (AU) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283745-A1 | NUCLEAR-TARGETED DNA REPAIR ENZYMES AND METHODS OF USE | DCLRE1A, UNG, DCLRE1B | PADI1 2467/4885PADI4 2634/4885PADI2 2388/4885 |
| US-20120225023-A1 | PEPTIDE PROTECTION AGAINST ULTRAVIOLET LIGHT TOXICITY | CHEK2, CHEK1, DDB1 | PADI1 636/4885PADI4 714/4885PADI2 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.